Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.56 |
| ▸ | DDO | Q99489 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5076094 | 1.00 | KDR (1.00) | KDRCHEK1PDGFRBFGFR1BRD4 | |
| SCHEMBL27489248 | 0.89 | KDR (0.79) | KDRCHEK1PDGFRBFGFR1BRD4 | |
| SCHEMBL30305373 | 0.88 | KDR (0.78) | KDRCHEK1PDGFRBFGFR1BRD4 | |
| SCHEMBL27488931 | 0.87 | KDR (0.77) | KDRCHEK1PDGFRBFGFR1DAO | |
| SCHEMBL5082453 | 0.87 | KDR (0.77) | KDRCHEK1PDGFRBFGFR1BRD4 | |
| SCHEMBL5208407 | 0.86 | KDR (0.74) | KDRCHEK1PDGFRBFGFR1BRD4 | |
| SCHEMBL5207806 | 0.86 | KDR (0.74) | KDRCHEK1PDGFRBFGFR1BRD4 | |
| SCHEMBL4779547 | 0.86 | KDR (0.74) | KDRCHEK1PDGFRBFGFR1BRD4 | |
| SCHEMBL5207582 | 0.85 | KDR (0.73) | KDRCHEK1PDGFRBFGFR1BRD4 | |
| SCHEMBL5076134 | 0.85 | KDR (0.72) | KDRCHEK1PDGFRBFGFR1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | UNIV YALE (US) | 2025-10-30 | — | — | US | claimed |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-07-22 | — | — | US | claimed |
| EP-4493222-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Yale University (US) | 2025-01-22 | — | — | EP | claimed |
| WO-2024227119-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-10-31 | — | — | WO | claimed |
| US-12083181-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2024-09-10 | — | — | US | claimed |
| EP-4414369-A2 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | Arvinas, Inc. (US) | 2024-08-14 | — | — | EP | claimed |
| US-11672779-B2 | Modulators of GTPases and their use | UNM RAINFOREST INNOVATIONS (US) | 2023-06-13 | — | — | US | claimed |
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-05-02 | — | — | US | claimed |
| US-20230097887-A1 | Bi-functional Molecules to Degrade Circulating Proteins | YALE UNIVERSITY | 2023-03-30 | — | — | US | claimed |
| US-20230083388-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-03-16 | — | — | US | claimed |
| US-11512083-B2 | Compounds and methods for the enhanced degradation of targeted proteins | ARVINAS OPERATIONS, INC. (US) | 2022-11-29 | — | — | US | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| US-20220267329-A1 | Dihydro-Spiro[Indoline-3:1'-Isoquinolin]-2-Ones and Their Analogues and Derivatives and Methods of Treating Cancer and Other Diseases | THE UNIV OF BUEA (CM) | 2022-08-25 | — | — | US | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| EP-4031543-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2022-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512083-B2 | Compounds and methods for the enhanced degradation of targeted proteins | VHL, MDM2, XIAP | KDR 493/4885CHEK1 1793/4885PDGFRB 1941/4885 |
| US-20230097887-A1 | Bi-functional Molecules to Degrade Circulating Proteins | MIF, GMFG, SERPINA6 | KDR 759/4885CHEK1 3641/4885PDGFRB 1204/4885 |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, ADRM1, MDM2 | KDR 319/4885CHEK1 453/4885PDGFRB 1004/4885 |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR2A | KDR 101/4885CHEK1 3374/4885PDGFRB 142/4885 |
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | SQSTM1, ATG7, BECN1 | KDR 2774/4885CHEK1 139/4885PDGFRB 4136/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | KDR 745/4885CHEK1 506/4885PDGFRB 1327/4885 |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | ASGR1, LDLR, FCGR3B | KDR 107/4885CHEK1 3882/4885PDGFRB 140/4885 |
| US-20230083388-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | KDR 101/4885CHEK1 3374/4885PDGFRB 142/4885 |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | KDR 2171/4885CHEK1 821/4885PDGFRB 3397/4885 |
| US-11672779-B2 | Modulators of GTPases and their use | CDC42, RAC1, ROCK1 | KDR 3654/4885CHEK1 588/4885PDGFRB 2117/4885 |
| US-20220267329-A1 | Dihydro-Spiro[Indoline-3:1'-Isoquinolin]-2-Ones and Their Analogues and Derivatives and Methods of Treating Cancer and Other Diseases | S1PR3, S1PR1, S1PR2 | KDR 403/4885CHEK1 2526/4885PDGFRB 281/4885 |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR3B | KDR 107/4885CHEK1 3882/4885PDGFRB 140/4885 |
| US-12083181-B2 | Bi-functional molecules to degrade circulating proteins | MIF, GMFG, FCGR1A | KDR 788/4885CHEK1 3891/4885PDGFRB 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.